Ras Jobs In Schweiz - 109 Job Positions Available

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle

About Us ten23 health is a human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. We support our clients in developing differentiated,

Background The Project Development and Management Unit (PDMU), in close collaboration with the Technical Coordination Unit (TCU), ensures the efficient management and implementation of the WMO project portfolio to address the needs of Member countries. The

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Nach über 30 Jahren geht bei uns eine Ära zu Ende. Unsere Kollegin im Verkaufsinnendienst verabschiedet sich in die Pension. Darum suchen wir dich im Verkaufsinnendienst Maschinen 100% Dein Beitrag & Verantwortungsbereich Du sorgst dafür, dass unsere

Applications are welcome from internal and external candidates. For all IOM vacancies, applications from qualified and eligible first-tier candidates are considered before those of qualified and eligible second-tier candidates in the selection process. For the purpose

To drive our continuous organic growth, we are constantly looking for highly qualified professionals. To strengthen our Regulatory Affairs (RA) team, we are looking for a (Senior) Regulatory Affairs Manager (permanent position, 100%, f/m/d). You will take

Die Re­ha­kli­nik Bad Zurzach bie­tet Re­ha­bi­li­ta­ti­on in al­len Fa­cet­ten auf ho­hem me­di­zi­ni­schem Ni­veau. Das re­ha­bi­li­ta­ti­ve An­ge­bot reicht von Neu­ro­lo­gie über Mus­ku­los­ke­let­tal/​Rheu­ma­to­lo­gie, Kar­dio­lo­gie bis hin zur Schlaf­me­di­zin (Kli­nik für Schlaf­me­di­zin). Im Schmerz­zen­trum Bad Zurzach wer­den im Rah­men

Begeisterst du dich dafür, Organisationen dabei zu unterstützen, das Potenzial von AI zu entfalten - von der Strategie bis zur erfolgreichen Einführung? Macht es dir Freude, dabei Governance sowie Responsible AI konsequent mitzudenken? Kannst du komplexe

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a

Die Re­ha­kli­nik Bad Zurzach bie­tet Re­ha­bi­li­ta­ti­on in al­len Fa­cet­ten auf ho­hem me­di­zi­ni­schem Ni­veau. Das re­ha­bi­li­ta­ti­ve An­ge­bot reicht von Neu­ro­lo­gie über Mus­ku­los­ke­let­tal/​Rheu­ma­to­lo­gie, Kar­dio­lo­gie bis hin zur Schlaf­me­di­zin (Kli­nik für Schlaf­me­di­zin). Im Schmerz­zen­trum Bad Zurzach wer­den im Rah­men

Zusammenfassung der Position The Clinical & Medical Affairs (CMA) Specialist Interventional reports to the EMEA CMA Manager and is responsible for supporting the safe and effective use of the Interventional portfolio in Austria & Switzerland. The

Description de lentreprise Chez Ardentis, on ne parle pas juste de valeurs, on les vit au quotidien. Excellence, innovation, développement personnel, esprit d’équipe et vision à long terme : c’est ce qui nous anime. Ici, on

Description de lentreprise Chez Ardentis, on ne parle pas juste de valeurs, on les vit au quotidien. Excellence, innovation, développement personnel, esprit d’équipe et vision à long terme : c’est ce qui nous anime. Ici, on